Ambeed.cn

首页 / 抑制剂/激动剂 / G蛋白偶联受体/G蛋白 / 内皮素受体 / Bosentan hydrate

波生坦水合物 /Bosentan hydrate {[allProObj[0].p_purity_real_show]}

货号:A404664 同义名: 波生坦 一水合物 / Ro 47-0203

Bosentan hydrate竞争性双重拮抗内皮素-1(ET)对ETA和ETB受体,在人体平滑肌细胞中Ki值分别为4.7 nM和95 nM。

Bosentan hydrate 化学结构 CAS号:157212-55-0
Bosentan hydrate 化学结构
CAS号:157212-55-0
Bosentan hydrate 3D分子结构
CAS号:157212-55-0
Bosentan hydrate 化学结构 CAS号:157212-55-0
Bosentan hydrate 3D分子结构 CAS号:157212-55-0
规格 价格 会员价 库存 数量
{[ item.pr_size ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}
{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_am, item.pr_size) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} 现货 咨询 - +
购物车0 收藏 询单

Bosentan hydrate 纯度/质量文件 产品仅供科研

货号:A404664 标准纯度: {[allProObj[0].p_purity_real_show]}
批次查询: 批次纯度:

全球学术期刊中引用的产品

Cell, 2024, 101755. Ambeed. [ A399663 ]
EMBO J., 2024. Ambeed. [ A295334 ]
JMC, 2024, 67(20): 18265-18289. Ambeed. [ A538667 , A341145 , A117430 , A172297 ]
JMC, 2024. Ambeed. [ A210558 , A1518164 ]
Cell Death Discov., 2024, 10, 436. Ambeed. [ A384235 ]
更多 >
产品名称 ET-A ET-B 其他靶点 纯度
BQ-123 +++

Endothelin A receptor, IC50: 7.3 nM

98%
Macitentan ++++

ET-A, IC50: 0.5 nM

+

ET-B, IC50: 391 nM

98%
Zibotentan ++

ET-A, IC50: 21 nM

99%+
Bosentan hydrate +++

ET-A, Ki: 4.7 nM

++

ET-B, Ki: 95 nM

98%
Ambrisentan 98%
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。

Bosentan hydrate 生物活性

靶点
  • ET-A

    ET-A, Ki:4.7 nM

  • ET-B

    ET-B, Ki:95 nM

描述 G protein-coupled receptor (GPCR) agonists through their receptors can transactivate protein tyrosine kinase receptors such as epidermal growth factor receptor and serine/threonine kinase receptors most notably transforming growth factor (TGF)‐β receptor (TβRI). Several GPCR agonists such as Ang II, thrombin, ET-1 can mediate the transactivation of a multitude of protein tyrosine kinase receptors[3]. Endothelin (ET) is an endothelium-derived 21-residue vasoconstrictor peptide. The ETs have three distinct isoforms, namely ET-1, ET-2, and ET-3. ET-1 is the most abundant isoform and the best characterized in vivo, and it is the only one that is constitutively released by the vascular endothelium[4]. Bosentan hydrate (BST) is a competitive dual endothelin receptor antagonist that is nonselective for both endothelin A and endothelin B receptors with a Ki of 4.1 - 4.7 nM[5]. It decreases both pulmonary vascular resistance and systemic vascular resistance and hence increases cardiac output without increasing the heart rate[6]. In a vivo study, the rats were intragastrically administered with 100 mg/kg bosentan half an hour after Paraquat exposure, and then once a day. After bosentan administration, the ET-1 and TGF-β1 content of the serum and lungs gradually decreased and were markedly lower than in the Paraquat group on the 21st day which indicated that early treatment with bosentan after Paraquat poisoning may be helpful in ameliorating lung injury and decreasing lung fibrosis[4]. In a study, bosentan was given orally (1000 mg b.i.d.) for 14 days to patients who were also being treated for chronic heart failure (CHF) with digitalis, angiotensin-converting enzyme inhibitors (ACEIs) and diuretics and the results demonstrated that addition of bosentan to ongoing therapy for patients with CHF reduced systemic and pulmonary vascular resistance and increased cardiac index, without affecting heart rate. Bosentan treatment of patients with CHF already receiving ACEIs and diuretics significantly decreased plasma aldosterone levels[5].

Bosentan hydrate 参考文献

[1]Ostrowski RP, Januszewski S, et al. Effect of endothelin receptor antagonist bosentan on plasma leptin concentration in acute myocardial infarction in rats. Pathophysiology. 2003 Sep;9(4):249-256.

[2]Clozel M, Breu V, et al. Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist. J Pharmacol Exp Ther. 1994 Jul;270(1):228-35.

[3]Sharifat N, Mohammad Zadeh G, Ghaffari MA, Dayati P, Kamato D, Little PJ, Babaahmadi-Rezaei H. Endothelin-1 (ET-1) stimulates carboxy terminal Smad2 phosphorylation in vascular endothelial cells by a mechanism dependent on ET receptors and de novo protein synthesis. J Pharm Pharmacol. 2017 Jan;69(1):66-72. doi: 10.1111/jphp.12654. Epub 2016 Dec 1. PMID: 27905105.

[4]Zhang Z, Jian X, Zhang W, Wang J, Zhou Q. Using bosentan to treat paraquat poisoning-induced acute lung injury in rats. PLoS One. 2013 Oct 14;8(10):e75943. doi: 10.1371/journal.pone.0075943. PMID: 24155875; PMCID: PMC3796527.

[5]Rubin LJ, Roux S. Bosentan: a dual endothelin receptor antagonist. Expert Opin Investig Drugs. 2002 Jul;11(7):991-1002. doi: 10.1517/13543784.11.7.991. PMID: 12084009.

[6]Lee HJ, Kang JH, Lee HG, Kim DW, Rhee YS, Kim JY, Park ES, Park CW. Preparation and physicochemical characterization of spray-dried and jet-milled microparticles containing bosentan hydrate for dry powder inhalation aerosols. Drug Des Devel Ther. 2016 Dec 13;10:4017-4030. doi: 10.2147/DDDT.S120356. PMID: 28008226; PMCID: PMC5167478.

Bosentan hydrate 实验方案

计算器
存储液制备 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.76mL

0.35mL

0.18mL

8.78mL

1.76mL

0.88mL

17.56mL

3.51mL

1.76mL

Bosentan hydrate 技术信息

CAS号157212-55-0
分子式C27H31N5O7S
分子量 569.629
别名 波生坦 一水合物 ;Ro 47-0203
运输蓝冰
存储条件

液体 -20°C:3-6个月-80°C:12个月

粉末 Sealed in dry,Room Temperature

溶解度

DMSO: 105 mg/mL(184.33 mM),注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO

无水乙醇: 50 mg/mL(87.78 mM),配合低频超声助溶,注意:无水乙醇开封后,易挥发,也会吸收空气中的水分,导致溶解能力下降,请避免使用开封较久的乙醇

动物实验配方

2% DMSO+30% PEG 300+2% Tween 80+water 5 mg/mL

Ambeed 相关网站 Ambeed.cn Ambeed.com
Ambeed
关于我们
联系我们
资讯中心
网站地图
产品手册
  • 批次文件查询
  • 客户支持
    技术支持
    专业术语
    缩略词释义
    质量手册
    产品咨询
    计算器
    活动政策
    订购方法
    积分商城
    活动声明
    联系我们
    400-920-2911 sales@ambeed.cn tech@ambeed.cn
    Ambeed 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务,不为任何个人或者非科研性质用途提供服务。